Navigation Links
Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
Date:9/10/2008

BEIJING, Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the market launch of Anflu(R), a seasonal influenza vaccine, for 2008-2009 Flu Season. Developed and manufactured by Sinovac, Anflu(R) is the only split influenza vaccine produced without preservatives in China. Sinovac is undertaking the sales and marketing program utilizing its established sales force to promote the adult dosage form of Anflu(R).

Utilizing the virus strain for the Northern Hemisphere recommended by the World Health Organization, Sinovac has commenced the production of Anflu(R) for the annual flu season based on its 2008-2009 production plan. The Chinese authorities have recently completed the review of the batch release process and approved the vaccine for launch. In August 2008, the China CDC issued the 2008 "Guidelines for Influenza Prevention and Control Technology" that highlighted the positive public health implications of receiving the seasonal flu vaccine, the target population and the extension of the vaccination duration. As an amendment to the 2007 version, the 2008 guidance expanded the recommended vaccination population to include people living in senior homes, nursing homes and chronic disease nursing facilities, along with childcare providers who are looking after infants less than six month in age.

Over the past year, Sinovac has expanded its manufacturing capacity with the construction of a pandemic influenza vaccine production line with annual capacity of 20 million doses using the grant from China's National Development and Reform Commission. The production line includes state-of-the-art automated production equipment along with an expanded packaging capability and affords Sinovac the ability to produce up to five million doses of Anflu(R). By leveraging the latest production technology, the quality of the Anflu vaccine will be enhanced.

In line with its efforts incorporate the latest technology, Sinovac has introduced new insulation packaging to facilitate vaccine distribution. Based on customer feedback, the packaging features color-coded insulated packaging that effectively utilizes ice to maintain the desired temperature. The updated packaging enables the shipping of 50 or 100 doses.

Mr. Weidong Yin, Chairman, President and CEO, commented, "We are very pleased to launch Anflu(R) in China for the 2008 - 2009 seasonal influenza season. By utilizing our state-of-the-art production capability, we are well positioned to deliver our adult dosage formulation to our target market in China."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Adjourns Annual General Meeting
2. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
3. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
4. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
5. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
6. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
7. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
8. Sinovac Biotech Holds Annual General Meeting
9. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
10. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
11. Sinovac Announces Adjournment of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:8/23/2017)... help is being enlisted in what,s thought to be the biggest study ... body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date of ... goal is to help advance scientific knowledge of the role of these ... The Microbiome ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
Breaking Biology News(10 mins):